Investigated
What is Nav1.7's role in osteoarthritis pain?
Short answer
Image: nature.com
The leading account is that Nav1.7 drives osteoarthritis through sensory-neuron pain signalling and chondrocyte control of calcium, secreted factors and cartilage damage; animal studies support both routes. A cautious view notes that most evidence is preclinical and broader Nav1.7 analgesic programmes have struggled clinically. The main disagreement is whether cartilage effects will translate into human disease modification.
The views on this question
Two lenses on the same evidence. Source weight and the primary source ratio show what each rests on.
Alternative
Source weight 58%Lens adapted to this topic: Translation and target-specificity concerns
A more cautious reading treats Nav1.7 as a promising mechanistic lead rather than an established osteoarthritis treatment. Pain relief in animals may arise largely from blocking neuronal excitability, while cartilage findings may not predict human disease modification. The wider Nav1.7 drug-development record also shows that strong genetic and in-vitro rationale has not reliably produced clinical analgesia.
- Nav1.7 blockade has repeatedly faced translation problems: compelling genetics and in-vitro pharmacology have not consistently produced analgesic efficacy in clinical development.
- Existing osteoarthritis evidence is predominantly from rodent models, including chemically or surgically induced disease, so human therapeutic benefit remains unproven.
- Pain reduction and structural improvement may be separable: neuronal Nav1.7 deletion reduced pain-like behaviour, whereas cartilage pathology was affected by chondrocyte deletion.
- A compound acting indirectly on Nav1.7 reduced pain-related outcomes in a rodent osteoarthritis model, but this does not establish clinical efficacy or prove that cartilage effects drive the benefit.